Philippe Monteyne News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Philippe monteyne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Philippe Monteyne Today - Breaking & Trending Today

Coave Therapeutics Strengthens Board of Directors

- Frederic Chereau named Chairman of the Board - Seasoned entrepreneur, Dr Claudia Mitchell, appointed Non-executive Director PARIS, Oct. 20, 2022 /PRNewswire/ Coave Therapeutics ....

United States , France General , Haute Normandie , Franche Comtér , Eleanor Perkin , Olivier Danos , Willem Broekaert , Sylvie Berrebi , Bruno Montanari , Claudia Mitchell , Kostenloser Wertpapierhandel , Astellas Pharma , Thierry Laugel , Guillaume Blavier , Frederic Chereau , Philippe Monteyne , Company Board Of Directors , Life Sciences For The Pacific Northwest Region , Paris University , I Research Fund , Ecole Des Ponts Business School , French National Institute Of Medical Research , International Management , University Of Paris , Seroba Life Sciences , Ligand Conjugates ,

Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers

LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies ....

United States , France General , Noord Holland , Marie Curie , Vincent Brichard , Eliane Piaggio , Bpifrance Innobio , Sacha Mann Takeda , Kostenloser Wertpapierhandel , Jacques Mizrahi Bioqube , Pasteur Mutualit , Institut Curie , Jean Francois Morin Bpifrance Innobio , Felice Verduyn Van Weegen , Dementia Fund , European Union Under Horizon , Philippe Monteyne Fund , Boehringer Ingelheim , European Fund For Strategic Investments , Takeda Pharmaceutical Company , Bioqube Factory Fund , Takeda Ventures Inc , Loncode Institute , European Union , Life Sciences , Bioqube Ventures ,

ExeVir Closes US$50M Series A Financing

ExeVir, a Ghent, Belgium-based company developing single domain antibody therapies providing broad protection against viral infections, closed its Series A financing raising a total of US$50m.
The financing, announced in March 2021, was led by Fund+ with participation from VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices. In conjunction with the funding, Caroline Thielen, Investment Manager at SRIW will join the Board of ExeVir Bio alongside Torsten Mummenbrauer, CEO of ExeVir Bio, Philippe Monteyne, Partner at Fund+, Erica Whittaker, Head of UCB Ventures, Jérôme Van Biervliet, Managing Director at VIB, Stef Heylen representing SFPI-FPIM, Professor Michel Kazatchkine as independent director and Katja Rosenkranz, Partner at V-Bio Ventures (observer), Joel Henneghien at Vives IUF (observer) and Louis Declerck at Fund+ (observer). ....

Louis Declerck , Michel Kazatchkine , Xavier Saelens , Erica Whittaker , Caroline Thielen , Van Biervliet , Katja Rosenkranz , Exevir Bio , Stef Heylen , Philippe Monteyne , Torsten Mummenbrauer , Nico Callewaert , Partner At Fund , V Bio Ventures , Investment Manager , Managing Director , Joel Henneghien , Professor Drs , எரிகா விட்டேக்கர் , கரோலின் திிேலென் , காடிய ரோசெங்கிரஞ்ச , கூட்டாளர் இல் நிதி , வ் உயிர் முயற்சிகள் , முதலீடு மேலாளர் , நிர்வகித்தல் இயக்குனர் ,

ExeVir Announces Close of US$50 million / EUR42 million Series A Financing

ExeVir Announces Close of US$50 million / EUR42 million Series A Financing
- Extends Series A with additional EUR19 million led by Fund+
- Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials
- XVR011 expected to be effective against SARS-Cov-2 and importantly its rapidly spreading variants and other Sarbecoviruses to emerge in the future
News provided by
Share this article
Share this article
GHENT, Belgium, March 16, 2021 /PRNewswire/ ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million. The financing was led by Fund+ with VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices. ....

France General , Waals Gewest , Region Flamande , Louvain La Neuve , Bruxelles Capitale , Michel Kazatchkine , Xavier Saelens , Prnewswire Exevir , Erica Whittaker , Caroline Thielen , Van Biervliet , Katja Rosenkranz , Exevir Bio , Torsten Mummenbrauer , Philippe Monteyne , Stef Heylen , Nico Callewaert , Investissement Federale Participatie , Belgian Federal Holding , European Life Sciences , Partner At Fund , Hasselt University , Ghent University , University Of Li , University Fund , Life Sciences ,

ExeVir Announces Close of US$50 million / EUR42 million Series A Financing

ExeVir Announces Close of US$50 million / EUR42 million Series A Financing
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

France General , Waals Gewest , Region Flamande , Louvain La Neuve , Bruxelles Capitale , Michel Kazatchkine , Xavier Saelens , Prnewswire Exevir , Erica Whittaker , Caroline Thielen , Van Biervliet , Katja Rosenkranz , Exevir Bio , Torsten Mummenbrauer , Philippe Monteyne , Stef Heylen , Nico Callewaert , Investissement Federale Participatie , Belgian Federal Holding , European Life Sciences , Partner At Fund , Hasselt University , Ghent University , University Of Li , University Fund , Life Sciences ,